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I was born on October 2, 1926. My mother died when I was 
8 days old. My father remarried. I had a stepmother and a 
difficult childhood. I had an inclination towards Medi-
cine but my father decided (as used to be the case in 
those days) that I should do a B.Sc. (Hons.) in Chemistry 
followed by a Master’s in Chemical Engineering. He had 
a pharmaceutical company in Lahore, which expanded 
during World War-II. He wanted me to work in this fac-
tory. The partition of the country witnessed an unexpec-
ted mass migration. We came out with just our shirts and 
trousers. The final year of my education was in ‘Camp’ 
facilities in Delhi. I obtained first division nonetheless in 
the final exam in 1948. During the following two years, 
one had to fend for oneself. I worked in more than one 
company selling imported paper and other commodities 
at a reasonable salary but without job satisfaction. I won 
a scholarship for postgraduate studies in France. Arriving 
in Paris in September 1950, I opted for Fermentation 
Technology. I was sent to a Division at the Institut Pasteur 
which maintained the right strains of yeast for the cham-
pagnes of France. We visited the winer es every now and 
then and were offered to ‘deguste’ the brews, at that time 
unfamiliar to my palate. The questions that I asked during 
these visits and in the lab, made the Head of this Division 
decide to transfer my Fellowship to the Biochemistry 
Division of the Institut Pasteur. After Macheboeuf’s death, 
Jaques Monod became the Head of this Division. He was 
not only a great scientist, original in his thinking and ap-
proach, he was a musician and played in chamber music 
concerts. His wife Odette had specialized in Tibetan art 
and worked at the Musée Guimet, the museum for oriental
arts in Paris. They had a great influence on cultivati g in 
me an appreciation for classical music and ancient cul-
tures. I was awarded the Doctorat d’Etat, Docteur es Sci-
ence (D.Sc.) in 1953, and though I was given a position 
in the Medical Research cadre, I moved to Germany in 
late 1954 as a Humboldt postdoctoral fellow. I returned 
to India in 1956 to join the newly established All India 
Institute of Medical Sciences (AIIMS) in New Delhi.  
1. Introduction: Early days at AIIMS 
I came to join the Institute on the afternoon of 9 August, 
1956. I had problems in finding this so called “pace-
setter” Institute. I was told to come beyond the Safdarjung 
Airport on the way to the Qutub Minar; no prominent 
building was visible. Passers by were few. It was largely 
an uninhabited area. After much searching, I came across 
a faded board dangling on a Neem tree which read “Of-
fice of the Member Secretary, All India Institute of Medi-
cal Sciences”. About 100 yards way stood four blocks of 
2 storey C-II type buildings. No formal gate or road led 
to these. It had rained and there were puddles of water. 
Bricks had been put here and there on which one could 
walk to reach the buildings. Inside one of them was the 
office of Dr K C K E Raja, the Member Secretary. It was 
a hot and humid day. He sat behind a huge table in his 
ves  with a towel hanging on the back of the chair. He 
beamed a welcoming smile. I was the second faculty 
member to join; Dr Nand Keswani had joined on the 
forenoon of the same day as Professor of Anatomy. We 
s ook hands and were given an office each in a C-II
building. We were told that the first batch of students 
would join on the 25th of September and were asked to get 
prepared to start classes. Th  stores officer and his assis-
tants had instructions to procure furniture, basic equip-
ment and other requirements. We could recruit essential 
technical staff for conducting practicals. From amongst 
the candidates sent by the Employment Agency, I recall 
recruiting Lal Singh, a young, fit-looking Sardarji who 
was a matriculate. He was resourceful. “Not possible“ or 
“Cannot be done” did not exist in his vocabulary. He 
would procure the chemicals, glasware and so on from 
somewhere or the other within the week for the practical 
class of the following week. Lal Singh stayed with me for 
20 ears or more, receiving promotions on the way to 
reach the highest level admissible in the technician cate-
gory. He put his hand to any task given to him and per-
formed it efficiently. To escape from having to carry out 
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the routine services of blood and urine chemistry, I had 
passed these to clinical pathology. Instead we offered 
specialized investigations on thyroid hormones, corticoids 
and sex steroids. We set-up also a Radio-Isotope labora-
tory for thyroid functions. Lal Singh was the chief tech-
nician in this lab. In his lab coat, he was addressed as 
Doctor Sahib by patients. With my encouragement, he 
studied Homeopathy as a part-time student and obtained 
a degree in it. He is today a reputed Homeopath with a 
flourishing practice and runs clinics in more than one part 
of Delhi. 
 The first 5 years of my service at AIIMS were primar-
ily devoted to sitting with the architects for planning and 
building laboratories in the pre-clinical block of the main 
building of AIIMS, drawing out of the list of equipment 
within the budget, floating te ders and screening quota-
tions. No formal research could be conducted till some 
wings of the pre-clinical block were ready. Of course we 
taught the undergraduates and had a lot of time to interact 
with students. This formed special bonds which have en-
dured to this day. A large percentage of our graduates went 
abroad for higher degrees and specialization. Most have 
stayed there and almost all have done exceptionally well. 
They occupy important positions and are loaded with money. 
They count amongst the highest income professionals in 
the USA. They have remained attached to their Alma Mater 
and to the teachers who taught them initially. Nearly all 
are enthusiastic members of the AIIMSONIANS Asso-
ciation and have a reunion each year to which they flock 
from far and wide. Every time I have gone for a confe-
ence or to give seminars, an AIIMSONIAN in Boston, 
San Francisco, Utah, Houston, Washington or elsewhere 
(they seem to be spread everywhere) has taken the initia-
tive to organize a dinner to which our former under-
graduate and post-graduate students congregate from a 
distance of up to 200km to relive old times. It is a touch-
ing experience. 
 In those early years, the size of the faculty at AIIMS 
was small. We met frequently. At least once a month, we 
had  party in some home and on the roof during summer 
months. These parties broke barriers and we got to know 
each other well. We sang songs; Rama (Prof. V Ramalin-
gaswami), Nand (Keswani) and I formed the famous trio, 
and as the evening progressed, there could be heard 
“Chal Chal re Naujavan”, “Ek Bangla Bane Niara” and 
other film songs of our college era. 
 Some of us (Nand Keswani, Ranjit Roy Chaudhry and 
I) wer  bachelors when we joined AIIMS. I used to stay 
with my uncle and aunt who had a sprawling Bungalow 
t 13 Rajpur Road, Civil Lines, near the University of 
Delhi. I used to commute this long distance in a Fiat car, 
which I had bought in very good condition from a socialite
friend of my aunt. It had a conspicuous emerald aqua colour
and an equally notable number, 202. The result was that 
my sorties in the evening, normal for a bachelor with 
spare time, could hardly remain a secret. Knowing French 
and German and having lived in Europe for six years, I 
made friends in the Embassy circle and with each party to 
which I was invited, the circle widened. The invitations 
in those days frequently demanded black tie or National 
dress, and for even non-formal dinners, a suit had to be 
worn. As I lived at a far end, my car carried on the back 
seat the dress for the evening and also riding shoes, 
Jodhpuris and polo cap. I became a life member of the 
Delhi Polo Club (DPC) and enjoyed going for horse rid-
ing at least once a week if not more often until post-
graduate education and research started and afternoons 
were no longer free. In those early post-Raj days, DPC 
used to organize cross-c untry rides on Sunday mornings 
starting at 5×30 or 6 AM and ending with breakfast around 
8 AM. It was inpractical to go to Rajpur Road after din-
ner and then come back to the polo ground in the Presi-
dent’s Estate by 5×30 AM. The outcome was that parties 
extending till the early hours became the preferred choice 
for Saturdays. 
 In the late nineteen sixties, Howard Goodman, Chief of 
Immunology at WHO (Geneva), visited India and some 
other south Asian countries along with Elvin Kabat, 
Melvin Cohn and a few other distinguished Immunolo-
gists. Their aim was to start a Centre for Research and 
Training (RTC) in Immunology for India and the South-
 
Figure 1. GPT as a research scholar at the Institut Pateur in 
Paris 1953. 
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East Asian regions. Amongst others, they visited me. I was 
then Professor and Head of Biochemistry at AIIMS. They 
spoke eloquently of their mission and, surprisingly,  
proposed to me to Head the envisaged WHO-RTC in 
Immunology. How I agreed to it, and how it led to the 
foundation of Immunology in the country, forms a part of 
this story. It had also a profound effect on my research, a 
transition from the basic quest to learn how growth pro-
moting and developmental hormones act on their target 
tissues to pursue problems of relevance to the country 
and devise possible solutions. 
 I was at that time deeply immersed in building an in-
dependent biochemistry Department at AIIMS and giving 
biochemistry its due place in medical teaching and re-
search. Biochemistry in most medical institutions was 
then a part of physiology. Its teaching was boring and 
minimal compared to the strides that the subject had 
made in life sciences. Clinicians visualized biochemistry 
in limited terms of urine and blood chemistry. Auto ana-
lysers were not yet an essential part of clinical chemistry 
labs. Laboratory investigations were done by a half-baked,
poorly motivated and reluctant “army” of technicians 
with the result that their repo ts were not reliable. Doctors 
made a diagnosis on basis of clinical features, whether 
supported or not by lab reports. My job was not only to 
introduce a contemporary, interesting and exciting course 
in biochemistry for students (who, at AIIMS, were the 
crème de la crème, admitted on a highly competitive  
basis), but also to educate my faculty colleagues on what 
modern biochemistry offered for their disciplines. Fortu-
nately the AIIMS faculty had both senior professors, se-
lected from various medical colleges in the country on 
grounds of eminence and experience in the practice of 
medicine, and bright associates recruited from abroad, 
who were receptive to modern biochemistry. As a result 
of our interaction, interdisciplinary modules for teaching 
were developed, where biochemistry was included along-
with pre- and para-clinical subjects for the teaching  
of clinical disciplines. A general course in modern bio-
chemistry, genetics and molecular biology was instituted 
for all post-graduate students in various subject  of medi-
cine and allied disciplines. This pattern of teaching not 
only benefited others but also the teachers in biochemis-
try. Most of us, including me, were non-medicals. Interdis-
ciplinary modules made us learn relevant aspects of other 
subjects. The Text Book of Biochemistry and Human  
Biology (Prentice Hall of India, 1980), which I wrote and 
edited, has contributions from teachers in many other 
disciplines. Three editions of the book have appeared by 
now. The niche that we created for biochemistry at 
AIIMS, as a full fledged independent department impart-
ing education at the undergraduate and post-graduate lev-
els, served as a model for similar departments at the 
Institute of Medical Scien es, Varanasi, Postgraduate 
Institute of Medical Education and Research, Chandigarh 
and elsewhere. 
2. Research during the initial years at AIIMS 
2.1 Mechanism of action of growth promoting and  
developmental hormones 
In the early years we had an Animal House and rudimen-
tary lab facilities. We observed that administration of 
pituitary growth hormone to rats increased their body 
we ght. It was logical to put forward the hypothesis that 
growth hormone enhanced the synthesis of proteins. Was 
it preceded by other metabolic events? The incorporation 
of 32-P into RNA, both mRNA and rRNA, was noticeably 
stimul tedby the hormone (Talwar et al 1964). In a par-
allel project, we worked on estradiol. On the removal of 
ovaries, the uterus of the rat shrunk markedly. Admini-
stration of estradiol in microgram amounts caused its 
perceptible growth. We hypothesized that the simulation 
of RNA synthesis was primary to the uterotrophic effect 
of estradiol. To test this hypothesis, a simple but conclu-
siv  experiment was done. Estradiol acted not only on the 
uterus, but also on vaginal cells. On ovariectomy, the 
uterus atrophied; this was quantifiable by weighing and 
histology, accompanied by a change of vaginal cytology 
obser d microscopically on aspirates. Injection of the 
hormone restored both organs. Topical application of 
Actinomycin-D locally on the vagina, thereby inhibiting 
DNA dependent RNA synthesis, prevented the hormone-
induced changes in the vagina. Uterine growth occurred 
normally in the same animal, implicating the critical role 
of RNA stimulated by the hormone for the subsequent 
development of the biological effects (Talwar and Segal 
1963). 
 Another feature of estradiol action was that it acted on 
some but not all organs of the body, though the hormone 
i  c rculation was accessible to all. We hypothesized that 
the s lective action could be due to the presence of recep-
tors for estradiol in some but not all tissues. This was 
found to be indeed the case. 3H-estradiol bound to a pro-
teinic fraction of the uterus, but not to similar extracts from 
lungs. The binding was highly specific. Labelled corti-
sone did not bind to the uterine fraction. A stereo-isom , 
17-a-estradiol, which has poor estrogenic property, bound 
poorly, whereas 17-b-estradiol, the active estrogen, had high 
binding with the uterine fraction (Talwar et al 1964). 
 A point to ponder was whether estradiol stimulated the 
transcription of specific genes. To answer this question, 
we made use of male chicks who do not normally make 
the egg yolk protein phosphvitin. As females made this 
protein, was it under the influence of th  female sex hor-
mone, estradiol? This could easily be tested by admini-
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stration of estradiol to male chicks. Estradiol induced the 
synthesis of this egg yolk protein in birds who would have 
never made it otherwise (Jailkhani and Talwar 1972a,b). 
 Another tantalizing question was why bone and carti-
lage growth occurred only up to the adolescent adult stage 
and not thereafter, even though pituitary growth hormone 
continues to be made and is in circulation. We employed 
cartilage from young and old animals and studied the 
effect of growth hormone on incorporation of 35S into
sulphated biopolymers. The tissue from aged animals had 
lost responsiveness to the hormone (Talwar et  1974c). 
 The thymus is the source of primary T lymphocytes 
which perform a key function in the immune response. 
The organ atrophies with age. We demonstrated that pi-
tuitary hormones exercise a stimulatory effects on uridine 
and sulphate incorporation into biopolymers at early stages 
of development. The receptors for growth homone were 
present on thymocytes from young but not aged animals 
(Saxena and Talwar 1974). The hormone influences not 
only the metabolism of thymocytes in young animals but 
also the degree of immune response to T dependent anti-
gens (Pandian and Talwar 1971). 
3. The Advent of Immunology 
I was immersed in and enjoying research on the mecha-
nism of action of hormones. There was no reason for 
shifting to the immunology. During my Docteur es Sci nce
work at the Institut Pasteur in Paris, I had studied and 
passed courses in Bacteriologie and Serologie et Immu-
nologie Generale, but during the 15 intervening years, 
immunology had changed vastly. Many advances had taken 
place. The structure of Immunoglobulins was established. 
The complexity and diversity of cell types constituting 
th  immune system was apparent. A lot was happening 
on the differentiation and maturation of these cells, as 
also on the genetics of the immune response. I needed to 
be a student again before I could justify taking up the 
position of Head, Research nd Training Centre (RTC), 
which was offered to me unexpectedly. Thus when the 
offer came, I was reluctant to take up the responsibility 
and suggested the names of others at AIIMS and other 
Institutions in the country. The Committee that chose me 
however visualized that Immunology had become a m-
lecular and cellular science and thought that my dep r-
ment was appropriate for locating the RTC. They were 
willi g to organize two teaching workshops on Advances 
in Immunology. A statement that floored me squarely 
was “I dia has the world’s largest number of leprosy pa-
tients (3×2 million at that time). Do we expect Americans 
to come and work on this disease to find solutions? Sci-
entists in India should take up the problems of India.” 
 I agreed to Head the WHO-RTC. While seeking Gov-
ernmen permission, Prof. P N Wahi, the then Director 
General of the Indian Council of Medical Research (ICMR), 
insisted that it should be first an ICMR and then a WHO 
Centre. Thus the Centre was named as the ICMR-WHO 
Research and Training Centre in Immunology. Our char-
ter was to organize an average of one course each year in 
contemporary immunology for teachers nd investigators 
in India and other countries in South East Asia. 
4. Research on leprosy 
Leprosy is a spectral disease – it has a spectrum of clini-
cal manifestations. The vast majority of humans (~ 99%) 
have innate resistance and do not get the disease on ex-
posure to Mycobacterium leprae. Amongst those who get 
it, the disease is manifest in pauci-bacillary and multiba-
cillary forms. The spectrum varies from polar tuberculoid 
(TT) form of leprosy with only a single lesion containing 
disintegrated bacteria to polar lepromatous leprosy (LL) 
with disseminated lesions all over the body full of prolif-
erating mycobacteria. The BL and LL type of multibacillary 
patients take 2 years or more to get cured by treatment 
with multi-drug therapy (MDT). They are the ones who 
perpetuate M. leprae and transmit the infection to others 
in the community. These patients have the maximal im-
mune deficit. Instead of killing the bacteria, their macro-
phages offer a hospitable territory for them to multiply. 
 Our initial urge was to understand the nature of the 
immunological deficit in multibacillary leprosy patients 
and, collaterally, to learn how the tuberculoid TT patients 
are able to kill M. leprae. Though AIIMS and local hos-
pitals in Delhi received leprosy patients, the cases were 
mixed up. Many came from Bihar and Nepal. I decided to 
go to a field area. The Danish ‘Save the Children’ NGO 
 
Figure 2. The picture recalls the discussion at AIR moderated 
by GPT with his ‘guru’ Jacques Monod (extreme right), close 
friend Feodor Lynen (extreme left) and R B Livingston (2nd 
from and left). 
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ran leprosy homes in Aska, Orissa and Pogiri, Andhra 
Pradesh. I ran into Dr Blum, the Doctor incharge of these 
clinics, in Delhi. He was willing to receive me and my 
co-workers and offered us living and working space and 
more importantly, fresh leprosy cases. I spent two sum-
mer vacations in these clinics along with two talented 
Ph.D. students, A D Krishnan and Vijay Lakshmi Mehra. 
We took with us a plexiglass hood, spirit lamps, cell cul-
ture media and of course plenty of plasticware. The clinic 
had microscopes and incubators but no CO2 i cubator. 
We utilized dessicators for keeping the cell culture dishes 
and plates in which a burning candle would extinguish 
automatically when the atmospheric CO2 concentration 
reached 5%. 
 Our studies in the field clinics during summer and in our
lab at AIIMS during the rest of the year indicated that the 
multibacillary patients did not have a generalized im-
mune defect. They reacted normally to most antigens and 
responded normally to ch lera and tetanus toxoid vac-
cines (Jha et al 1971). Their lymphocytes did not react to 
M. leprae and did not undergo antigen driven blast trans-
formation (Talwar et al 1972). Depending on the stage of the 
disease and the category to which the patient was classi-
fiable, the defect was either intrinsic and or acquired s a 
consequence of M. leprae infection. Acquired immuno-
suppression was relieved by treatment when the patients 
became bacillary negative (Nath et l 1977). 
 A key question concerned the determinants which made 
macrophages competent to kill M. leprae, which was the 
case in polar tuberculoid TT patients, whereas the same 
cell in polar lepromatous LL cases offered a hospitable 
territory for the proliferation of M. leprae. To answer 
this, we needed an in vitro system. M.  leprae does not 
grow in any culture medium and requires obligatorily a 
host cell for multiplication. Monocytes from human pe-
ripheral blood cells can be isolated and made to differentiate
in culture to macrophages. We required a quantifiable 
method to determine the growth of M. leprae. Bacterial 
counts could not be employed, as the bacillus is a very 
slow grower and takes 13 days to divide. The bacilli form 
globi and the initial inoculum coming from the patients 
has an unknown number of living and dead bacilli. We 
hit on the idea of employing 3H-thymidine for incorpora-
tion into DNA. In ‘permissive’ conditions, bacilli would 
make DNA preparatory to division. On the other hand, 
the host cell, the macrophages, lack thymidine kinase and 
hence would not incorporate radiolabelled thymidine (Talwar 
et al 1974a). Employing monocyte derived macrophages 
and lymphocytes from TT and LL patients in various 
combinations, we could determine that the defect in LL 
patients was in both macrophages and lymphocytes and 
in their interaction via cytokines generated to respond to 
M. leprae (Talwar et al 1974b). This results in a failure 
to recognize some key component(s) of M. leprae. 
5. Can there be a vaccine for leprosy? 
Traditionally, vaccines have been made with killed or 
attenuated micro-o ganisms. This approach was not ten-
able for leprosy as, inspite of dead and live M. lepraein 
th  bo y, no immunity develops. We looked for cross-
r active mycobacteria; sixteen were inv stigated and 
their ability to cause blast transformation of lymphocytes 
from tuberculoid (TT) and LL patients determined. The 
rationale was that TT patients have an autoregressive 
diseas ; thus there should be a positive reaction with 
lymphocytes of these patients. However, in addition, the 
lymphocytes of LL patients who do not respond to M. 
leprae should respond to the cross-reactive mycobacteria. 
Also their ability to generate cytokines such as macro-
phage migration inhibitory factor (MIF) was measured. 
On basis of these studies, five mycobacteria got short-
listed. In the next stage, their ability to cause the 
Mitsuda/Dharmendra reaction, which is a delayed hyper-
sensitivity skin reaction in vivo was investigated in five 
centres located in different parts of the country (to mini-
miz  the influence of enviromental mycobacteria to 
which patients may be sensitized). From the ensemble of 
these studies an atypical, fast growing, non-pathogenic 
mycobacterium, bearing the code “w” was identified. 
Foureen papers in the Golden Jubilee issue of L prosy in 
India 1978 describe this work. 
 After pre-clinical toxicology, permissions were ob-
tained from the Drugs Controller of India and Institu-
tion l Ethics Committee to carry out phase-I safety trials 
in LL patients cured by drugs. As their specific immune 
deficit persists, the study was to see whether by immuni-
zation with autoclaved Mycobacterium w (Mw), they 
became positive to M. leprae lepromin. Sixteen of the 19 
patients converted to lepromin positivity, and the conver-
sions were stable on retest after 9–11 months (Chodhuri 
et l 1983). 
 The next task was to investigate the efficacy of the 
v ccine. By the very nature of the disease (99% being 
protected naturally and 2–10 years required for the dis-
ease to manifest after infection), prophylactic trials had 
to be of a long duration and involve a large number of 
subjects. We therefore undertook immuno-therapeutic 
trials in multibacillary patients. When detected, such pa-
tients had to be put on a multi-drug regime (MDT) on 
ethical and public health grounds. Thus all patients re-
ceived supervised MDT and every alternate patient was 
given the vaccine or a placebo intradermally once every 3 
months. Trials were conducted at the Ram Manohar Lo-
hia and Safdarjung Hospitals by Drs S A Zaheer and A K 
Walia under Profs H K Kar and R S Misra. These were 
highly systematic and thorough trials. Bacterial index 
(BI) determination and histopathology on each biopsy 
was done by two independent laboratories and a clinical 
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assessment was made at ach stage by more than one ex-
perienced leprologists. These phase-II/III trials conducted 
in 388 patients in Delhi and 1100 patients in Kanpur 
Dehat demonstrated that the BI declined significantly 
faster in patients receiving the vaccine. Their clinical 
improvement was better. Surprisingly, no significant un-
toward reactions were observed. In fact the vaccine 
cleared the granulomas expeditiously. Figure 3 is a pre-
sentative illustration of two patients receiving MDT + 
Mw vaccine. At the end of 24–29 months of treatment 
57×3% LL patients could be released from treatment in 
the MDT + vaccine group, whereas their number was 
11×9% on MDT alone. 
 What was interesting in other independent trials was 
the finding that with Mw vaccine, no viable M. leprae 
remained in patients skin after 6 months, whereas it took 
around 18 months for all M. leprae to be dead in patients 
receiving MDT alone (Katoch et al 1995). 
 These impressive results called for phase-III/IV fi ld 
trials, which were conducted in over 4 lakh subjects in a 
 
 
Figure 3. Effect of combining immunotherapy with chemotherapy on clinical improve-
ment of multibacillary patients. (a) MD, a lepromatous leprosy patient after 4 doses of 
vaccine and after 8 doses of the vaccine. (b) RPS, a BL patient at the time of enrollment 
and after 2 doses of the vaccine. 
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community block of Kanpur Dehat as part of the National 
Leprosy Control Programme. These were double blind 
trials and the code was made and kept with ICMR. There 
were four groups, two of patients receiving MDT ± vac-
cine/placebo. Another two groups comprised the healthy 
household contacts of leprosy patients, who received ei-
ther the Mw vaccine or placebo (1/8 dose of tetanus toxoid 
vaccine). Three surveys were carried out by Dr Kiran 
Katoch after 3, 6 and 9 years of vaccination. The vaccine 
conferred protection against leprosy in 68%, 60% and 
28% of household contacts as per thes  surveys indicat-
ing a fairly good protection up to 6 years after which a 
booster of this killed vaccine would be desirable (Sharma 
et al 2005). 
 Mw vaccine is the first leprosy vaccine to reach the 
public. It has received the approval of the Drugs Control-
ler General of India for marketing. It is made by M/s 
Cadila Pharma and is marketed as “Immuvac”. Immuvac 
has also the approval of the US Federal Drugs Admini-
stration. 
6. Ancilliary benefit of the vaccine 
While transferring the technology to Cadila, the company 
asked for a biological assay to confirm that it was Mw 
and not a mutant that had been grown. A Ph.D. student of 
ours, Indira Guleria Singh, had done studies during my 
time at NII (see below) on 4 genetic strains of mice, 2 of 
them Balb/c and C57BL/6 were responders and 2 others 
C3H and CBA non-responders to BCG. Mw vaccine how-
ever protected all 4 strains of mice against tuberculosis 
(Singh et al 1991). We also noted that guinea pigs, highly 
sensitive to tuberculosis, can resist challenge with M. 
tuberculosis H37Rv on prior immunization with Mw. This 
is a test routinely performed by Cadila on the batches of 
Mw grown by them. Immuvac accelerates significantly 
the clearance of acid-fast (presumably tubercular) bacilli 
in the sputum of the patients. More interestingly, the 
benefit is more seen in chronic and relapse cases. Based 
on these preliminary results, the Department of Biotech-
nology has funded a multi-centre trial for the utility of 
employing Immuvac for tuberculosis. 
7. Necessity to persevere and withstand onslaughts 
My work in leprosy and also on beta hCG vaccine  
(see below) was faced with innumerable hurdles. The 
“Crab Syndrome” is often cited, where you are pulled 
back at various stages of your work by your own peers. 
Phase-I trials of the Mw vaccine were delayed. Newspa-
pers published, with prominent headlines, that Mw was in 
fact a different bacillus and I was guilty of unethical 
practices. None of these charges have stood the test of 
time, but they were distasteful. G ne sequencing was to 
reveal that Mw is distinct from 33 other mycobacteria 
listed in the Data Bank (Reddi et al 1994). 
8. The National Institute of Immunology 
As head of the Jawaharlal Nehru Fund, Prime Minister 
Indira Gandhi used to meet the Jawaharlal Nehru Fellows 
for about half a day every year. She used to listen to what 
e were doing and ask for suggestions on what could be 
done to promote science and other scholastic endeavours 
in the country. I made a case for immunology, specially 
the beneficial aspects of the subject. Just the introduction 
of a handful of vaccines for immunization of children has 
brought down drastically the infant mortality. More vac-
cines have to be developed for infections prevalent in the 
country, and also diagnostic assays, for which hybridoma 
technology has ushered in a new era. She asked for a 
proposal. I remember to have written the proposal for a 
“Centre for Immunology” during a transatlantic flight, 
helped by lavish servings of champagne and caviar. Mrs 
Gandhi sent the proposal to her advisor Prof. M G K 
Menon, who consulted many experts. He also referred the 
proposal to the then Director-General Indian Council of 
Medical Research, Prof. V Ramalingaswami, as well as 
the Director-General of the Indian Council of Agricul-
tural Research. All assessed the proposal positively and 
added to its scope. This is how the National Institute of 
Immunology proposal blossomed. I was asked to join as 
the first Director. I did so in an honorary capacity, retain-
in  my professorship at AIIMS till I could, because I 
needed a working laboratory base. I was insistent on lo-
cating NII in a University. Jawaharlal Nehru University 
in Delhi allotted us a piece of land sandwiched between 
the Vice-Chancellor’s residence and the Institute of Mass 
Communication. It had rocks and ravines with three rain 
water drains. Many considered me crazy for accepting 
this ite, instead of getting several acres across the 
Jamuna river. The Institute was inaugurated by Prime 
Minister Rajiv Gandhi on October 6, 1986. In less than 3 
years, the main central building, auditorium, experimen-
tal animal house, primate facility, hostel for post-gra-
duates, and 20 resid nces for faculty were built and made 
functional. This may well be the fastest pace at which a 
composite research institute has been built, nationally or 
internationally, without compromising on quality of con-
struction. To achieve this a number of strategies were 
adopted. To save costs, no leveling was done. Innova-
tively designed buildings would hug the landscape. The 
environment was vastly improved by planting trees. Water 
h rvesting and reuse of water for vegetation was done. 
Hume pipes were laid in drains to create space for resi-
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dences and other amenities. Electricity was drawn from 
more than one grids to minimize central breakdowns in 
supply. Generators and stabilizers were installed to en-
sure uninterrupted energy supply of constant voltage and 
frequency. A non-Central Public Works Department route 
was taken to reduce the cost and also assure a good quality 
of construction. 
 We created about 30 positions of staff scientists. Each 
had the inbuilt provision of rising to the highest level 
without the necessity of obtaining fresh sanctions. I had 
to argue and insist on this structure. I thought it would 
discourage politics and internal rivalries and encourage 
merit and performance as the yardstick to move upwards. 
Thanks to an enlightened expenditure secretary, Mr Es-
waran, and the visionary support given by Prof. M G K 
Menon, these regulations were accepted, as was the rec-
ommendation that the salary and status of the Director, 
NII be equivalent to those of a Secretary to the Govern-
ment of India. Each scientist was initially appointed on 
contract for 5 years. His or her performance was to be 
reviewed in the 4th year and for those on a fast track, the 
review could be requested after 3 years. Five floating 
positions were created for scholars, who were selected on 
a highly competitive basis, so as to accommodate them as 
staff scientists after they had completed their Ph.D. In-
variably the scholars would go abroad as Post-doctoral 
fellows. The floating positions were meant to give them a 
place to return and remain active before they found better 
positions in other institutions, universities or industry. 
 NII was planned in its staffing pattern and facilities as 
a multidisciplinary Institute, offering inhouse, the possi-
bility of inter-laboratory collaboration for taking a re-
search lead to a potential product. Laboratories with 
competent staff were established for recombinant DNA 
technology, microbiology, virology, reproductive immu-
nology, embryo biotechnology, structural biology, or-
ganic biochemistry, molecular genetics and product deve-
lopment. Scientists with productive backgrounds and 
high caliber contributions in each field were the initial 
appointees. Rather than deprive Institutions within India 
of their talented staff, the opportunity of joining was 
given to Indian scientists abroad to the extent possible. 
9. Immunological approaches to  
control of fertility 
Few will disagree that population growth is a major n-
tional problem. With an annual increment of one Australia 
equivalent on an already large base exceeding a billion, 
our resources are under high stress. India has 2% of the 
world’s land area and 16% of the population. The mes-
sage of family planning has got across, but there is a need 
for additional, more suitable methods for persons to use. 
Tubal or vasal ligation are, for all practical purposes, 
terminal methods and are accepted only after the birth of 
several children (including at least one son). I tra-Uterine 
Devices entail extra bleeding, which already naemic 
women can not support for long. Steroid pills demand 
daily motivation and are essentially an urban proposition. 
They do have side effects though acceptable for the bene-
fit of protection they offer. Implants cause irregular bleed-
ing and are not acceptable to all. With this background, we 
thought of developing a reversible method, which may 
require periodic intake, may not demand daily motivation, 
and ideally, should not disturb the normal physiology of 
the woman (as is the case with contraceptive st roids which 
block ovulation). We thought of a vaccine against human 
chorionic gonadotropin (hCG), a dimer made of a and b 
subunits. HCG is made by the woman at a very early stage 
of conception. Eggs fertilized in vitro make it. It is criti-
cal t  the implantation of the embryo; marmoset embryos 
exposed to anti-b-hCG antibodies fail to implant. 
 b-hCG being a ‘self’ protein, the woman would not 
normally make antibodies reacting with it. To make it 
immunogenic, we linked it with tetanus toxoid (TT). The 
choice of TT was deliberate. In seventies, tetanus ac-
counted for the largest number of deaths of women at 
parturition. b-hCG-TT was thus a double function vac-
cine to induce immunity against tetanus, besides mobiliz-
ing T cells to help make antibodies against hCG. The 
proof of concept was obtained by the demonstration that 
it indeed generated anti-hCG and anti- etanus antibodies 
in women (Talwar et al 1976). The antibody response 
wa  reversible. It did not impair ovulation, nor cause any 
noteworthy change in reproductive and other hormones 
(Contraception 1976). 
 The main drawback of b-hCG-TT vaccine given with 
the mild human-use-permissible adjuvant aluminum hy-
 
Figure 4. The picture shows a pioneer in the vaccine field, 
Jonas Salk, along with Françoise Gilot, associate of Picasso 
and herself a known artist, and Prof. and Mrs G P Talwar at a 
symposium reception at Delhi. 
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drochloride was that it raised antibodies of respectable 
titre in only 25–30% of women. How could we augment 
its immunogenecity? As bio-effective antibodies are con-
formation reading antibodies, the antigen to be presented 
should retain the native conformation of hCG, so that the 
immuno-reactivity of the antibodies would be high. b-
hCG has 12 half cysteines linked to form 6s-s bonds; 
these have to be intact. For binding to the receptor on the 
target tissue, b-hCG combines with a-hCG and the dimer 
not only fits in the receptor but also transduces the signal 
for biological action. So ideally we should use the dimer 
as the antigen. However as the  subunit of hCG is com-
mon to the human follicle stimulating, thyroid stimulatng 
and lutenizing hormones, it may evoke cross-r acti ns. 
We thought of employing a heterospecific (ovine) a sub-
unit. The ability of a subunits to combine with the b sub-
unit has been retained through evolution, and the ovine a 
forms a heterospecies dimer (HSD) with b-hCG. HSD 
had higher immunogenecity and superior bioneutraliza-
tion capacity (Talwar et al 1988). 
 After toxicology, Drugs Regulatory and Ethical ap-
provals, we carried out phase-I comparative safety and 
immunogenecity studies with the initial vaccine (b-hCG-
TT), and the new HSD-TT (Kharat et al 1990; Talwar et al 
1990). 
 We had thus an improved immunogen. The next and 
the key question was would this vaccine prevent preg-
nancy in women? Nobody had provided any direct evi-
dence for anti-hCG antibodies counteracting pregnancy 
in vivo, even though the sera from women immunized in 
phase-I clinical studies had bio-efficacy in vitro systems. 
How much of the antibody would be minimally necessary 
to prevent pregnancy was unknown. By various calcula-
tions, we fixed a threshold of 50 ng/ml bio-neutralization 
capacity titre for determining whether at these antibody 
titres or higher, women are protected. 
 The phase-II efficacy trials on the HSD-TT/DT vac-
cine were undertaken in three centres. Fertile, sexually 
active women with at least two live children were en-
rolled for the trial. Many of them had had MTP (medical 
termination of pregnancy) done more than once as the 
available methods for birth control were not suitable for 
them and they used the methods irregularly. They readily 
gave their informed consent to enroll in the trial. In all, 
148 women were immunized with the vaccine. None of 
them experienced any inconvenience. After the initial 
three doses, they had the option to take boosters as and 
when the titres declined below 50 ng/ml. Many remained 
in the trial for over 2½ years taking boosters now and 
then. All women continued to have regular cycles. These 
were ovulatory as shown by the luteal phase progesterone 
levels. Their libido remained intact. The method was highly 
effective and only one pregnancy occurred in 1224 cycles 
at or above 50 ng/ml. It was perfectly reversibl , women 
conceiv d in the first cycle below 35 ng/ml (Talwar et al 
1994). The trials were described as a landmark (Aldhous 
1994). 
 The immunogenecity of this improved version of the 
vaccine was much better than the initial prototype b-
hCG-TT. 110/148 women (~ 74%) raised antibody titres 
above 50 ng/ml and in 60% of them persisted for 3 
months or more above the protective threshold. Th  ad-
juvants used were the permissible alhydrogel and SPLPS 
in the first injection only. 
 The feasibility of preventing pregnancy in a reversible 
manner was clearly demonstrated by this and follow up 
work (Talwar et al 1997; see also the Editorial on the 
article in the same issue). The protection was achieved 
without blocking ovulation or impairing bleeding pro-
files. The antibodies acted by interception of embryo im-
plantation. The luteal phase was not lengthened of those 
who ovulated and should normally have conceived with 
high frequency of intercourse. 60–80% of recipients with 
protective titres for an infectious disease vaccine would 
be highly acceptable. However, for a fertility control vac ine 
more than 90–95% of protection is required. Thus the 
vaccine has to undergo further product development, al-
though the proof of concept was largely provided.
10. Cordon ablated 
The day in October 1994, when I was told politely but 
bluntly the decision of the governing body that my term 
at NII would finish on the 30th of October and that I 
would have to leave by the end of the month, left me 
feeing injured. The Institute that I had built from scratch 
to a high standing nationally and internationally was un-
ble to provide me working space. The Institute authori-
ties could not extend my emeritus position, even though I 
was actively involved in the vaccine project and the Insti-
tute wanted to continue further work on the vaccine.  
An International Development Research Centre (IDRC)  
Canada grant for developing the vaccine was to be left 
behind with the Institute; the patents for the vaccine 
granted in many countries of the world were of course 
assigned to the Institute. These thoughts troubled my 
mi d. I was in a further quandary. With great effort, the 
10th International Congress of Immunology, due in 1998, 
was allotted to New Delhi. This was the first time ever 
that this Congress was to be held in a developing country. 
I was the President of the Congress. I was even denied 
space for the congress secretariat. One day when I was 
going for lunch, I ran into Dr Krishan K Tiwari, at that 
tim the Director of the International Centre for Genetic 
Engineering and Biotechnology (ICGEB), Delhi. He 
asked me why I looked grave and depressed unlike the 
Talwar he had known since many years. On hearing of 
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my predicament he offered, subject to the approval of Dr 
Flaschi, the Director General of ICGEB, the posi ion of a 
senior consultant at ICGEB. He would prvi e space for 
the Secretariat of the Congress – in his eyes, an honour to 
India. I would get laboratory space but would have to 
fend for research money. I could join on the day after I 
left NII. The Rockfeller Foundation transferred the grant 
on Female Reproductive Health to ICGEB on the prin-
ciple that their grants were given to investigators, not  
to institutions. Thus started another phase of my profes-
sional life. 
11. Praneem polyherbal and Basant for  
reproductive tract infections (RTIs) and  
sexually transmitted diseases (STDs) 
The prevalence of RTIs causing abnormal vaginal dis-
charge (AVD) is about 30% in women attending hospi-
tals in Delhi. A report by Bang et al (1989) puts the 
figure at 50% in rural Maharashtra. The syndrome is 
caused by a variety of organisms ranging from Tricho-
monas, Gardenerella vaginalis, Candida, aerobic and 
anaerobic microbes, viruses, Chlamydia, etc. Depending 
on the diagnosis of the causative micro- rganisms, local 
medication and/or antibiotics are given. Facilities for 
diagnosis exist in only few Institutions and the treatment 
is mostly empirical. Could we make a formulation with a 
wide-spectrum action? We looked for ingredients with 
action on various genital pathogens. Neem (Azadirachta 
indica) leaf has been used traditionally as a general anti-
septic for wounds and its twig for oral hygiene. A num-
ber of tri, tetra terpenoids have been characterized from 
neem with actions on viruses, fungi, microbes and nema-
todes. Thus neem leaf extracts were prepared and puri-
fied to a point that they do not become unstable and their 
spermicidal action on human sperm assessed. To expand 
the range and potency of action, purified saponins from 
Sappindus mukerosi, quinine hydrochloride and Mentha 
citrata oil were added to the formulation. Praneem poly-
herbal (PPH) inhibited the growth of N. gonorrhea, 
multi-drug resistant (MDR) urinary tract Escherichia coli 
and MDR Staph. aureus. It acted against Candida albi-
cans, C. krusei and C. tropicalis. At Johns Hopkins, it was 
observed to prevent the transmission of Herpes simplex-2 
and Chlamydia trachomatis by the vaginal route in pro-
gestin sensitized mice. At the Institut Pasteur in Paris, 
Francoise Barré Sinoussi and Annie David demonstrated 
its potent virucidal action against HIV-I (Talwar et al 
2000). 
 Praneem polyherbal tablets have successfully under-
gone phase-I safety and phase-II fficacy trials. Taken 
intravaginally for seven nights with soap washed fingers, 
95% of women with AVD get fully or partially relieved 
of their symptoms. Speculum examination indicates com-
plete cure in 69% of women. The PPH tablet is now 
poised for phase-III large-scale trials in 10 Centres of the 
Indian Council of Medical Research. Meanwhil  PPH has 
been licensed to M/s Panacea Biotech who will supply 
the large number of PPH tablets for the phase-III tri l . 
They will also make available the requisite tablets manu-
factured under Good Manufacturing Practices (GMP) 
conditions for the ongoing phase-II trials at National 
AIDS Research Institute (NARI) Pune, where its ability 
to prevent the transmission of HIV-AIDS by the hetro-
sexual route is being investigated. 
 Basant is another polyherbal formulation developed by 
us, which is dispensed as a cream. It contains purified 
curcumin, amla extracts, Aloe vera, quinine hydrochlo-
ride and Mentha citrata oil. It has also a wide spectrum 
action against genital pathogens including HIV-III and 
human papilloma viruses. It will be undergoing trials for 
its abil ty to eleminate HPV16,18 and other types of papil-
loma viruses in women with cervical dysplasia who are 
positive for HPVs. If found effective, this will be a valu-
able therapeutic for elimination of a virus which is asso-
ciated with carcinoma of the cervix. 
12. Registration of a non-profit Trust 
I as  Jawaharlal Nehru Fellow (JNF) from December 
1979 to November 1981. This unique Fellowship relieved 
me from the routine duties of teaching and administration 
and gave freedom to write, study or do research of one’s 
own liking. I wrote a monograph, “Immunology of Con-
traception”, which was published by Edward Arnold 
London, The Year Book in the USA and, a translation in 
Russia. 
 The p oneering work of Köhler and Milstein in 1975 
on fusion of an antibody making cell with a cell capable 
of multiplying perpetually, fascinated me greatly and we 
generated a hybridoma secreting a monoclonal antibody 
(MoAb) against hCG. This MoAb was rated amongst the 
best on grounds of its high affinity and high specificity. 
The fellowship rules gave full rights to the Fellows of the 
royalties on account of scholastic work and of research 
done during the Fellowship years. I was thus given rights 
on this MoAb, which I licensed to M/s Carter Wallace/ 
Wampole Laboratories as the key reagentfor their preg-
ancy diagnosis kits. To my knowledge, this was the first 
Biotech product from India licensed to a US company. 
From this, over 3 years I received the unexpectedly high 
royalty of US$ 780,000 after cutting US taxes. I used the 
amount to create a non-profit charitable Trust named the 
Talwar Research Foundation (TRF). The returns from the 
TRF corpus were initially spent on monetary support to 
help bright women scientists whose career is disrupted by 
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marriage or children, to return to research and complete a 
Ph.D. Over 35 women scientists have availed of TRF 
grants. Money has also been given for education and 
boarding of orphans and stipends for bright children com-
ing from economically deprived backgrounds. The TRF has 
also given generously for the rehabilitation of leprosy 
patients. 
 In the late 1990’s, the trustees of the Foundation (Prof. 
V Ramalingaswami, M S Swaminathan, R A Mashelkar 
and N K Ganguly besides a distinguished lawyer, R K P 
Shankardass, UNESCO goodwill Ambassador Madanjeet 
Singh, who is my old classmate and friend sinc  the 
1940s, my aunt and daughter) asked me to seek recogni-
tion for TRF as a Scientific and Industrial Research Or-
ganization which, if obtained, would enable the Foun-
dation to claim exemption from customs duty in addition 
to income tax. I was told that such recognition was given 
only to organizations conducting research themselves. 
Giving fellowships to women scientists or charities to 
orphans and leprosy patients did not entitle the Founda-
tion to be considered. It so happened that at that time it 
was decided that the laboratory space given to me in 
ICGEB had to be vacated to house a National Brain Re-
search Centre. Dr Flaschi gave me several months to 
make alternate arrangements. Faced with imminent ouster, 
I wondered whether to call it a day, as far as research
goes. I was 73 on October 2, 1999. My projects were 
midway, however, and I was reluctant to be compell d to 
close. I was able to convert an adversity to a challenge. I 
decided to build a laboratory for TRF. Using my own 
money I bought 500 square yards of land near my resi-
dence in Neb Valley. We started building a laboratory 
there at the fastest posible pace. My son Pratap Raj is an 
architect based in Boston. He felt that I needed more land 
to make a Polyhouse (polymer covered Green House) etc. 
and he sent me the money to buy another 700 square 
yards. We were functional within a year. The Department 
of Scientific and Industrial Research gave TRF recogni-
tion as SIRO, to be renewed every 3 years and currently 
valid ill 2007. 
13. Epilogue 
It is my intention to continue teaching and research till 
my last days. There will be no ‘retirement’ from TRF. 
Praneem and Basant are on clinical trials and may find 
use in the management of RTIs and prevention of STDs 
including HIV, and elimination of HPV infections lead-
ing to carcinoma of the cervix. We have humanized 4 
monoclonal antibodies. These recombinant chimeric an-
t bodies are expected to be employed for therapy of ad-
vanced stage tumours, often refactory to available drugs. 
There is a possibility of revival of the hCG vaccine on a 
platform evoking immune response in 99% of women. 
An Indo-US grant application pertaining to it is awaiting 
approval. Finally we have perfected a multimer recombi-
nant vaccine against luteinizing hormone-releasing hor-
mone (LHRH) (Gupta et al 2004; Raina et al 2004;  
 
 
Figure 5. GPT in 2004 receiving DSc (hc) from Dr A P J Abdul Kalam, President of 
India. 
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Talwar et al 2004). LHRH is a unique decapeptide common 
to both males and females which controls the generation 
of sex steroids (besides gametes). The vaccine may find 
application in hormone-d pendent cancers (prostate and 
breast). 
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